Switch theme
Sign up to access all valuation multiples
Hapvida Participacoes Investimento SA is the medical-hospital and dental care company. The company and its subsidiaries are mainly engaged in the sale of health insurance plans and delivering the majority of medical assistance at its own hospitals, clinics, imaging diagnostics and laboratories; and the sale of dental insurance plans for services provided by an accredited network.
1979
20K+
LTM Revenue $5.3B
LTM EBITDA $672M
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hapvida has a last 12-month revenue (LTM) of $5.3B and a last 12-month EBITDA of $672M.
In the most recent fiscal year, Hapvida achieved revenue of $5.1B and an EBITDA of $581M.
Hapvida expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hapvida valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3B | XXX | $5.1B | XXX | XXX | XXX |
| Gross Profit | $1.5B | XXX | $580M | XXX | XXX | XXX |
| Gross Margin | 29% | XXX | 11% | XXX | XXX | XXX |
| EBITDA | $672M | XXX | $581M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $289M | XXX | $269M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $68.3M | XXX | -$114M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hapvida's stock price is BRL 3 (or $1).
Hapvida has current market cap of BRL 21.2B (or $3.7B), and EV of BRL 28.5B (or $5.0B).
See Hapvida trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $3.7B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hapvida has market cap of $3.7B and EV of $5.0B.
Hapvida's trades at 1.0x EV/Revenue multiple, and 8.6x EV/EBITDA.
Equity research analysts estimate Hapvida's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hapvida has a P/E ratio of 54.6x.
See valuation multiples for Hapvida and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBIT | 17.4x | XXX | 18.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 54.6x | XXX | -32.7x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | 11.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHapvida's last 12 month revenue growth is 9%
Hapvida's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $16K for the same period.
Hapvida's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hapvida's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hapvida and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Star Health Insurance | XXX | XXX | XXX | XXX | XXX | XXX |
| Qualicorp | XXX | XXX | XXX | XXX | XXX | XXX |
| Accolade | XXX | XXX | XXX | XXX | XXX | XXX |
| AIX Inc. | XXX | XXX | XXX | XXX | XXX | XXX |
| Clover Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hapvida acquired XXX companies to date.
Last acquisition by Hapvida was XXXXXXXX, XXXXX XXXXX XXXXXX . Hapvida acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hapvida founded? | Hapvida was founded in 1979. |
| Where is Hapvida headquartered? | Hapvida is headquartered in Brazil. |
| How many employees does Hapvida have? | As of today, Hapvida has 20K+ employees. |
| Who is the CEO of Hapvida? | Hapvida's CEO is Mr. Jorge Fontoura Pinheiro Koren de Lima. |
| Is Hapvida publicy listed? | Yes, Hapvida is a public company listed on BVMF. |
| What is the stock symbol of Hapvida? | Hapvida trades under HAPV3 ticker. |
| When did Hapvida go public? | Hapvida went public in 2018. |
| Who are competitors of Hapvida? | Similar companies to Hapvida include e.g. Star Health Insurance, Qualicorp, Accolade, AIX Inc.. |
| What is the current market cap of Hapvida? | Hapvida's current market cap is $3.7B |
| What is the current revenue of Hapvida? | Hapvida's last 12 months revenue is $5.3B. |
| What is the current revenue growth of Hapvida? | Hapvida revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Hapvida? | Current revenue multiple of Hapvida is 1.0x. |
| Is Hapvida profitable? | Yes, Hapvida is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hapvida? | Hapvida's last 12 months EBITDA is $672M. |
| What is Hapvida's EBITDA margin? | Hapvida's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Hapvida? | Current EBITDA multiple of Hapvida is 7.5x. |
| What is the current FCF of Hapvida? | Hapvida's last 12 months FCF is $219M. |
| What is Hapvida's FCF margin? | Hapvida's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Hapvida? | Current FCF multiple of Hapvida is 22.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
